TY - JOUR
T1 - Natural products targeting cancer stem cells
T2 - A revisit
AU - Cui, Jiahua
AU - Qian, Jiajun
AU - Chow, Larry Ming Cheung
AU - Jia, Jinping
N1 - Funding Information:
This paper has been financially supported by the Startup Fund for Youngman Research at SJTU (SFYR at SJTU, Grant No. 19X100040082) and the Hong Kong Scholar Program (Grant No. XJ2015032).
Funding Information:
The authors acknowledge the financial support received from the Startup Fund for Youngman Research at SJTU and the Hong Kong Scholar Program.
Publisher Copyright:
© 2021 Bentham Science Publishers.
PY - 2021/10
Y1 - 2021/10
N2 - Background: The proposed central role of cancer stem cells (CSCs) in tumor development has been extended to explain the diverse oncologic phenomena such as multidrug resistance, metastasis and tumor recurrence in clinics. Due to the enhanced expression of ATP-binding cassette transporters and anti-apoptotic factors, stagnation on G0 phase and the strong ability of self-renewal, the CSCs were highly resistant to clinical anticancer drugs. Therefore, the discovery of new drug candidates that could effectively eradicate cancer stem cells afforded promising outcomes in cancer therapy. Objective: Natural products and their synthetic analogues are a rich source of biologically active compounds and several of them have already been recognized as potent CSCs killers. We aim to provide a collection of recently identified natural products that suppressed the survival of the small invasive CSC populations and combated the drug resistance of these cells in chemotherapy. Results: These anti-CSCs natural products included flavonoids, stilbenes, quinones, terpenoids, polyketide antibiotics, steroids and alkaloids. In the present review, we highlighted the therapeutic potential of natural products and their derivatives against the proliferation and drug resistance of CSCs, their working mechanisms and related structure- activity relationships. Conclusion: Meanwhile, in this survey, several natural products with diverse cellular targets such as the naphthoquinone shikonin and the stilbene resveratrol were characterized as promising lead compounds for future development.
AB - Background: The proposed central role of cancer stem cells (CSCs) in tumor development has been extended to explain the diverse oncologic phenomena such as multidrug resistance, metastasis and tumor recurrence in clinics. Due to the enhanced expression of ATP-binding cassette transporters and anti-apoptotic factors, stagnation on G0 phase and the strong ability of self-renewal, the CSCs were highly resistant to clinical anticancer drugs. Therefore, the discovery of new drug candidates that could effectively eradicate cancer stem cells afforded promising outcomes in cancer therapy. Objective: Natural products and their synthetic analogues are a rich source of biologically active compounds and several of them have already been recognized as potent CSCs killers. We aim to provide a collection of recently identified natural products that suppressed the survival of the small invasive CSC populations and combated the drug resistance of these cells in chemotherapy. Results: These anti-CSCs natural products included flavonoids, stilbenes, quinones, terpenoids, polyketide antibiotics, steroids and alkaloids. In the present review, we highlighted the therapeutic potential of natural products and their derivatives against the proliferation and drug resistance of CSCs, their working mechanisms and related structure- activity relationships. Conclusion: Meanwhile, in this survey, several natural products with diverse cellular targets such as the naphthoquinone shikonin and the stilbene resveratrol were characterized as promising lead compounds for future development.
KW - Cancer stem cells
KW - Chemotherapy
KW - Flavonoids
KW - Multidrug resistance
KW - Naphthoquinones
KW - Natural products
KW - Resveratrol
KW - SARs
KW - Shikonin
KW - Stilbenes
UR - http://www.scopus.com/inward/record.url?scp=85110656271&partnerID=8YFLogxK
U2 - 10.2174/0929867328666210405111913
DO - 10.2174/0929867328666210405111913
M3 - Journal article
C2 - 33820513
AN - SCOPUS:85110656271
SN - 0929-8673
VL - 28
SP - 6773
EP - 6804
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
IS - 33
ER -